CMS Administrator Dr. Oz proposes deep cuts to the 340B drug program to lower Medicare costs. Learn how this affects ...

CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...

The rule, released Thursday, builds on Trump administration’s priorities, including cutting Medicare reimbursement for drugs ...

CMS would set 340B drug payment at ASP–33.4%, lowering Medicare and beneficiary drug outlays while redistributing equivalent ...

A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing policy debate.

The Centers for Medicare and Medicaid Services’ annual outpatient hospital pay increase proposal has come with a potential ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Halo340B today called on Federally Qualified Health Centers and other 340B covered entities to take a more strategic and mission-driven approach to understanding their 340B gross-to-net performance.

An autoimmune disease diagnosis can mark the start of a difficult medical battle. But for too many patients, it also marks ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...